Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 105
- Registration Number
- NCT01169805
- Locations
- ๐ฐ๐ท
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2015-01-27
- Target Recruit Count
- 29
- Registration Number
- NCT01046240
- Locations
- ๐ช๐ธ
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT01031498
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Gruppo Italiano Studio Linfomi
- Target Recruit Count
- 86
- Registration Number
- NCT01018758
- Locations
- ๐ฎ๐น
Gruppo Italiano Studio Linfomi, Modena, Italy
Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00982995
- Locations
- ๐บ๐ธ
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 239
- Registration Number
- NCT00967499
- Locations
- ๐บ๐ธ
Precision Trials, Phoenix, Arizona, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
๐บ๐ธUniversity of Kansas Medical Center, Kansas City, Kansas, United States
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 150
- Registration Number
- NCT00828295
- Locations
- ๐ท๐บ
Federal State Institution St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation
๐ท๐บState Healthcare Institution 'Regional Pediatric Clinical Hospital', Yaroslavl, Russian Federation
๐บ๐ฆCherkassy Regional Hospital, Pediatric Surgery Department, Cherkassy, Ukraine
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 59
- Registration Number
- NCT00684463
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2008-04-25
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 208
- Registration Number
- NCT00666783
- Locations
- ๐จ๐ณ
Xijng Hospital, Xi,an, Shaanxi, China
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00661674
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.